NVDA−4.40%AAPL+1.23%GOOGL−3.15%MSFT−2.23%AMZN−4.57%TSM−4.52%SPCX−9.14%META−6.98%
StockVS

NASDAQ · Biotechnology · USD

Parabilis Medicines, Inc. (PBLS) Stock Analysis

Parabilis Medicines, Inc. (PBLS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 22, 2026

PBLS

$26.92

−$0.93 (−3.34%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PBLS with… →

PBLS Key Statistics

As of Oct 22, 2026
Trading
Open
$28.03
Previous Close
$27.85
Day's Range
26.58–28.29
52-Week Range
22.66–42.49
Volume
911.95K
Valuation
Market Cap
$3.33B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−9.51
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$145.89M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
121.95M
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
796.03K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Parabilis Medicines, Inc. (PBLS) has a market capitalization of $3.33B.

In fiscal 2025, PBLS reported revenue of $0.00.

PBLS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$145.89M—
2024$0.00−$117.91M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$152.08M−$145.89M—
2024$0.00—−$126.13M−$117.91M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Parabilis Medicines, Inc. (PBLS) is capitalised at $3.33B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 145.

PBLS last closed at $26.92 on October 22, 2026. That is −$0.93 (−3.34%) against the previous close. Over the past 52 weeks the price has ranged from $22.66 to $42.49. The latest close sits 18.8% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $145.89M. Trailing earnings per share are −9.51.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

The record shows no dividend for PBLS.

2026 is still running; the total return is −14.81% year to date.

Peer Comparison

Parabilis Medicines, Inc. (PBLS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Parabilis Medicines, Inc. PBLS $3.33B —
Vertex Pharmaceuticals Incorporated VRTX $135.64B 31.0
Regeneron Pharmaceuticals, Inc. REGN $84.33B 20.3
Moderna, Inc. MRNA $80.90B —

The Biotechnology industry average P/E ratio is 16.6x. Parabilis Medicines, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$135.64B

 REGN

Regeneron Pharmaceuticals, Inc.

$84.33B

 MRNA

Moderna, Inc.

$80.90B

 ARGX

argenx SE

$55.07B

 ONC

BeOne Medicines AG

$43.49B

 RVMD

Revolution Medicines, Inc.

$40.23B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

 JNJ

Johnson & Johnson

$644.91B

 ABBV

AbbVie Inc.

$503.96B

 UNH

UnitedHealth Group Incorporated

$381.46B

 MRK

Merck & Co., Inc.

$363.27B
View all Healthcare stocks →

About Parabilis Medicines, Inc.

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Visit website →